In vivo investigations into the carbene gold anticancer drug candidates NHC*-Au-SCN and NHC*-Au-Scyclo
|Title:||In vivo investigations into the carbene gold anticancer drug candidates NHC*-Au-SCN and NHC*-Au-Scyclo||Authors:||Walther, Wolfgang
|Permanent link:||http://hdl.handle.net/10197/10501||Date:||12-Sep-2018||Online since:||2019-05-16T11:13:34Z||Abstract:||The anticancer drug candidate 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene gold(I) thiocyanate (NHC*-Au-SCN) and its cyclohexane thiolate derivative (NHC*-Au-Scyclo) exhibited very good activity against human colon cancer with GI50 values against human HCT116 colon cancer cells of 0.40 and 1.65 μM, respectively. In addition, inhibition of the mammalian thioredoxin reductase (TrxR) was observed with IC50 values of 0.77 ± 0.34 µM for NHC*-Au-SCN and 13 ± 4 µM for NHC*-Au-Scyclo?). This encouraged maximum tolerable dose (MTD) experiments in mice, where MTD values of 10 mg/kg for NHC*-Au-SCN and 30 mg/kg for NHC*-Au-Scyclo were determined with single injections to groups of 2 mice. In the subsequent tumor xenograft experiment NHC*-Au-SCN and NHC*-Au-Scyclo were applied three times at two doses in groups of 6 HCT116 tumor-bearing NMRI:nu/nu mice. The control group comprising 6 mice was treated with the solvent only. NHC*-Au-SCN at the dose of 5 and 10 mg/kg and NHC*-Au-Scyclo at the higher dose of 15 and 30 mg/kg showed tolerability towards the drugs, while no significant body weight loss was seen in both groups. NHC*-Au-SCN exerted only weak antitumoral activity reflected by T/C values of 0.81 and 0.65. The tumor volume growth reduction induced by NHC*-Au-Scyclo was better, with optimal T/C values of 0.58 and 0.31 being observed at doses of 15 mg/kg and 30 mg/kg, respectively. Alterations in dosing and/ or application schedules might further improve the antitumoral activity, particularly for NHC*-Au-Scyclo.||Funding Details:||University College Dublin||Type of material:||Journal Article||Publisher:||Research Trends||Journal:||Trends in Cancer Research||Volume:||13||Start page:||63||End page:||70||Copyright (published version):||2018 Research Trends||Keywords:||Carbene-gold anticancer drug; NCI 60 cancer cell panel; Thioredoxin reductase; HCT116 colon cancer; Xenograft mouse model||Other versions:||http://www.researchtrends.net/tia/abstract.asp?in=0&vn=13&tid=57&aid=6176||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Chemistry Research Collection|
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.